2Chany MG,Strader DB, Thomas DL, et al. Diagnosis,management and treatment of hepatitis Call update, Hepatology, 2009,49: 1335-1374.
3Carithers RL, Emerson SS . Therapy of hepatitis C: meta-analysis of interferon slfa-2b trials Hepatology, 1997,26 (3 Suppll ) : 83 88.
4Wills RJ. Clinical pharmacokinetic of interferons Clin Pharmacokinet, 1990,19:390 -399.
5Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 1998, 282: 103-107.
6Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon-a therapy is associated with more favorable long term response in patients with chronic hepatitis C. J Med Virol, 1995,46: 109.
7Ge D, Fellay J, Thomason AJ, et al. Genetic variation in 11.28B predicts hepatitis C treatment induced viral clearance Nature,2009, 461:399 -401.
8Hayes CN,Kobayashi M,Akuta N, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut, 2011,60 : 261-267.
